| Literature DB >> 17179671 |
Baek-Nam Kim1, Soon-Im Choi, Nam-Hee Ryoo.
Abstract
We report on the investigations and interventions conducted to contain an extended outbreak of Serratia marcescens bacteriuria that lasted for years in a neurosurgical intensive care unit (NSICU). A case-control study was performed to identify the risk factors for S. marcescens acquisition in urine. In case patients, urine sampling for tests and central venous catheterization were performed more frequently before the isolation of S. marcescens. Case patients were more frequently prescribed third-generation cephalosporins. Adherence to hand antisepsis was encouraged through in-service educational meetings and infection control measures, especially concerning the manipulation of indwelling urinary catheters, were intensified. The outbreak persisted despite the reinforcement of infection control measures. However, no patient has newly acquired the organism in the NSICU since December 2004. Multiple factors, including inadequate infection control practices and inappropriate antimicrobial usage, possibly contributed to the persistence of this S. marcescens outbreak. Healthcare workers should consistently follow infection control policies to ensure quality care.Entities:
Mesh:
Year: 2006 PMID: 17179671 PMCID: PMC2721949 DOI: 10.3346/jkms.2006.21.6.973
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Fig. 1Distribution of patients who newly acquired Serratia marcescens in urine from July 1999 through February 2005.
Results of case-control study
SD, standard deviation; SAH, subarachnoid hemorrhage; ICH, intracranial hemorrhage; IVH, intraventricular hemorrhage; NSICU, neurosurgical intensive care unit; ER, emergency room; NS, not significant.
Multivariate analysis of risk factors associated with acquisition of Serratia marcescens in urine
Fig. 2PFGE fingerprints of Serratia marcescens isolates. One major clone was shared by the isolates shown in lanes 1, 2, 4, and 5 (type A) with 2 closely-related isolates (lanes 3 and 6 designated as subtypes A1 and A2, respectively). Five isolates showed a different pattern (type B, lanes 7-11). Antimicrobial susceptibility patterns of the isolates above are shown according to clone type in Table 3. M, Lambda DNA size marker; C, control (E. coil O157: H7G5244).
Antimicrobial susceptibility patterns of Serratia marcescens isolates for which PFGE was performed
PPR, piperacillin; PPR/TZ, piperacillin/tazobactam; CTX, cefotaxime; CFP, cefepime; IMI, imipenem; CIP, ciprofloxacin; GM, gentamicin; AMK, amikacin.